About Us

About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

My Watchlist
Indicators
Cabling Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarcoma Oncology Center Leverages BostonGene’s AI-Driven Molecular and Immune Profiling Platform to Identify Novel Treatment Options for Patients with Advanced Cancers

By: via Business Wire

BostonGene’s Identification of Elevated CCNG1 Levels in Multiple Cancer Types Unlocks Potential of Tumor-Targeted Gene Therapy

BostonGene, a leading AI-based molecular and immune profiling solutions provider, and the Sarcoma Oncology Center, announced a collaboration to expedite the availability of DeltaRex-G. This groundbreaking platform therapy, authorized by the FDA's Center for Biologics Evaluation and Research (CBER), holds immense promise for patients battling advanced pancreatic cancer, osteosarcoma, soft tissue sarcoma, and breast cancer. The designation of DeltaRex-G, a CCNG1 inhibitor, as a platform therapy with the potential to incorporate other FDA-approved drugs, was enabled by BostonGene's pivotal identification of elevated CCNG1 levels in these different cancer types.

Sarcoma Oncology Center, located in Santa Monica, California, is a cancer treatment and clinical research center, recognized for its clinical trials and clinical expertise in treating patients with sarcoma.

Sarcomas, rare tumors that originate in bone and connective tissue, pose a unique treatment challenge since most sarcoma subtypes have no approved standard of care treatment and are typically chemotherapy-refractory. The best treatment approach for patients with advanced sarcomas consists of understanding their unique tumor molecular profile, and selection of a therapy that is “matched” to the molecular alterations.

Sarcoma Oncology Center partnered with BostonGene for its innovative computational platform, which leverages AI-based molecular and immune profiling. The BostonGene Tumor Portrait™ test uncovers intricate correlations between different “omic” profiles including genomic alterations on tumor cells, profiling of a tumor’s immune landscape, and the potential to use these findings to understand which patients are most likely to benefit from treatment. The authorization of investigational agent DeltaRex-G, a CCNG1 inhibitor, as a platform therapy open to incorporating other FDA-approved drugs and immunotherapies stems from BostonGene's pivotal identification of heightened CCNG1 levels across all tumors tested, including osteosarcoma, soft tissue sarcoma, pancreas, breast, urothelial and testicular carcinoma.

"Our partnership with BostonGene provides us with an AI-driven, molecular perspective of the dynamic tumor microenvironment and immune landscape, thereby expanding the treatment horizons for our patients," said Erlinda Gordon, MD. "This collaboration has broadened our cancer treatment options, as BostonGene is the only molecular profiling company reporting on the CCNG1 expression in tumors," said Sant P. Chawla, MD, Director at Sarcoma Oncology Center.

“We are pleased to be working with the Sarcoma Oncology Center to support their efforts in personalizing treatments for their patients. Our advanced sequencing and analytical capabilities will be indispensable in guiding treatment decisions for these cancer patients who would otherwise have very limited options," said Nathan Fowler, MD, Chief Medical Officer at BostonGene.

About BostonGene Corporation

BostonGene has a mission to provide transformative, AI-integrated molecular analytics and biomarker discovery for precision matching of therapies to improve the lives of patients living with cancer and other immune-related diseases. BostonGene’s concierge-service model provides customized client solutions using a multi-omic approach prioritized for real-world impact to optimize standard-of-care therapies, accelerate research and provide cost-effective, measurable data-driven results. BostonGene’s tests reveal key drivers of each patient’s unique disease profile, including an in-depth profile of the immune microenvironment, actionable mutations, biomarkers of response to diverse therapies, and recommended therapies. Through these comprehensive analyses, BostonGene’s tests generate a personalized roadmap for therapeutic decision-making for each patient. For more information, visit BostonGene at http://www.BostonGene.com.

Contacts

More News

View More
Alphabet: Time to Take Profits, Buy, or Wait for a Pullback?
Via MarketBeat
Topics Artificial Intelligence
Tickers GOOGL
Hershey vs. Mondelez: Which Stock Wins Chocolate Season?
Via MarketBeat
Topics Economy
Tickers HSY MDLZ PEP
Thor Industries Tracking for New Highs in 2026
Via MarketBeat
Topics Economy
Tickers THO
Cintas Stock Sends a Clear Buy Signal as Momentum Builds
Via MarketBeat
Topics Government
Tickers CTAS
It's a Good Time to Build a Position in KB Home
Via MarketBeat
Tickers KBH
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.